Trelegy ellipta ingredients?

What chemicals make up Trelegy Ellipta?

Trelegy Ellipta is a medication containing three active ingredients: fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. According to the manufacturer, GlaxoSmithKline, and DrugPatentWatch.com, these ingredients play a crucial role in the medication's effectiveness.

- Fluticasone furoate is a corticosteroid that helps reduce inflammation in the lungs.
- Umeclidinium bromide is a muscarinic receptor antagonist that relaxes muscles in the airways and increases airflow to the lungs.
- Vilanterol trifenatate is a long-acting beta-adrenergic receptor agonist that helps open airway passages.

All three ingredients are combined within Trelegy Ellipta, making it a triple therapy for the treatment of chronic obstructive pulmonary disease (COPD).

How do Trelegy Ellipta's ingredients compare with other medications?

In comparison with other medications, Trelegy Ellipta's unique combination of ingredients provides a distinct approach to managing COPD symptoms. While other medications may focus on single ingredients or separate treatments, Trelegyt Ellipta's triple therapy offers a single inhaler for comprehensive symptom management.

When does the patent expire for Trelegy Ellipta's active ingredients?

Information on patent expiry for individual ingredients is readily available on DrugPatentWatch.com. The patent for fluticasone furoate, for example, has expired. Conversely, umeclidinium bromide and vilanterol trifenatate also have patents that remain active but are set to expire soon. For exact dates, it is best to consult current information from reliable sources.

Sources:

[1] GlaxoSmithKline Inc. Trelegy Ellipta. www.gsk.com/en-gb/products/pi/trelegy-ellipta

[2] Drug Patent Watch. Trelegy Ellipta. www.drugpatentwatch.com/drug/156390/

[3] National Institutes of Health. Trelegy Ellipta (fluticasone furoate, umeclidinium bromide, and vilanterol). www.ncbi.nlm.nih.gov/medlineplus/druginfo/meds/a618027/